Hong Kong Stock Movement | SIHUAN PHARM (00460) Rises Nearly 4%, Recent Approval of New "Youthful Needle" Specifications Further Enhances Regenerative Aesthetic Product Market Layout

Stock News11:10

SIHUAN PHARM (00460) rose nearly 4%, up 3.94% to HK$1.32 by the time of writing, with a turnover of HK$12.825 million. Recently, the company announced that six new specifications of the polylactic acid facial filler (commonly known as the "Youthful Needle"), independently developed by its subsidiary Mei Yan Space Biotechnology (Jilin) Co., Ltd., have been officially approved by China's National Medical Products Administration. This marks another significant advancement following the product's initial approval, further enhancing the company's market positioning in the field of regenerative aesthetic products. Prior to this specification expansion, the product was already approved in three specifications: 45mg/bottle, 75mg/bottle, and 150mg/bottle, catering to different needs such as preventative management, combination therapy, and comprehensive rejuvenation. The newly approved specifications—60mg/bottle, 80mg/bottle, 100mg/bottle, 110mg/bottle, 120mg/bottle, and 130mg/bottle—will further enrich the product selection spectrum.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192384078?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-23 11:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192384078","market":"fut","top_or_hot":-1,"title":"Hong Kong Stock Movement | SIHUAN PHARM (00460) Rises Nearly 4%, Recent Approval of New \"Youthful Needle\" Specifications Further Enhances Regenerative Aesthetic Product Market Layout","media":"Stock News","content":"<p>SIHUAN PHARM (00460) rose nearly 4%, up 3.94% to HK$1.32 by the time of writing, with a turnover of HK$12.825 million. Recently, the company announced that six new specifications of the polylactic acid facial filler (commonly known as the \"Youthful Needle\"), independently developed by its subsidiary Mei Yan Space Biotechnology (Jilin) Co., Ltd., have been officially approved by China's National Medical Products Administration. This marks another significant advancement following the product's initial approval, further enhancing the company's market positioning in the field of regenerative aesthetic products. Prior to this specification expansion, the product was already approved in three specifications: 45mg/bottle, 75mg/bottle, and 150mg/bottle, catering to different needs such as preventative management, combination therapy, and comprehensive rejuvenation. The newly approved specifications—60mg/bottle, 80mg/bottle, 100mg/bottle, 110mg/bottle, 120mg/bottle, and 130mg/bottle—will further enrich the product selection spectrum.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement | SIHUAN PHARM (00460) Rises Nearly 4%, Recent Approval of New \"Youthful Needle\" Specifications Further Enhances Regenerative Aesthetic Product Market Layout</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement | SIHUAN PHARM (00460) Rises Nearly 4%, Recent Approval of New \"Youthful Needle\" Specifications Further Enhances Regenerative Aesthetic Product Market Layout\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-23 11:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SIHUAN PHARM (00460) rose nearly 4%, up 3.94% to HK$1.32 by the time of writing, with a turnover of HK$12.825 million. Recently, the company announced that six new specifications of the polylactic acid facial filler (commonly known as the \"Youthful Needle\"), independently developed by its subsidiary Mei Yan Space Biotechnology (Jilin) Co., Ltd., have been officially approved by China's National Medical Products Administration. This marks another significant advancement following the product's initial approval, further enhancing the company's market positioning in the field of regenerative aesthetic products. Prior to this specification expansion, the product was already approved in three specifications: 45mg/bottle, 75mg/bottle, and 150mg/bottle, catering to different needs such as preventative management, combination therapy, and comprehensive rejuvenation. The newly approved specifications—60mg/bottle, 80mg/bottle, 100mg/bottle, 110mg/bottle, 120mg/bottle, and 130mg/bottle—will further enrich the product selection spectrum.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"","article_id":"1192384078","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192384078","pubTimestamp":1769137817,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SIHUAN PHARM (00460) rose nearly 4%, up 3.94% to HK$1.32 by the time of writing, with a turnover of HK$12.825 million. Recently, the company announced that six new specifications of the polylactic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1593":"医美概念股","02800":"盈富基金","00460":"四环医药","BK1191":"制药","BK1515":"抗疫概念","BK1610":"ETF&股票定投概念","BK1600":"工业大麻"},"translate_title":"港股动向|四环医药(00460)涨近4%，近期“青春针”新规格获批进一步增强再生美学产品市场布局","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1,"02800":1},"content_text":"SIHUAN PHARM (00460) rose nearly 4%, up 3.94% to HK$1.32 by the time of writing, with a turnover of HK$12.825 million. Recently, the company announced that six new specifications of the polylactic acid facial filler (commonly known as the \"Youthful Needle\"), independently developed by its subsidiary Mei Yan Space Biotechnology (Jilin) Co., Ltd., have been officially approved by China's National Medical Products Administration. This marks another significant advancement following the product's initial approval, further enhancing the company's market positioning in the field of regenerative aesthetic products. Prior to this specification expansion, the product was already approved in three specifications: 45mg/bottle, 75mg/bottle, and 150mg/bottle, catering to different needs such as preventative management, combination therapy, and comprehensive rejuvenation. The newly approved specifications—60mg/bottle, 80mg/bottle, 100mg/bottle, 110mg/bottle, 120mg/bottle, and 130mg/bottle—will further enrich the product selection spectrum.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192384078","isCrawlerRequest":true}